dalteparin has been researched along with Hospital Acquired Pneumonia in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audley, GG | 1 |
| Frankenfeld, P | 1 |
| Dlamini, S | 1 |
| Raubenheimer, P | 1 |
| Hoare, J | 1 |
| Cairncross, L | 1 |
| Van den Berg, R | 1 |
| Gule, MV | 1 |
| Calligaro, G | 1 |
1 other study available for dalteparin and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling; | 2020 |